

21 July 2026

ASX Compliance Pty Ltd  
Level 40, Central Park  
152-158 St Georges Terrace  
Perth WA 6000

Attention: Mr Damian Dinelli  
Principal Adviser, Listings Supervision

Via Email: [ListingsCompliancePerth@asx.com.au](mailto:ListingsCompliancePerth@asx.com.au)

Dear Mr Dinelli,

**Lotus Resources Limited (ASX:LOT) – ASX Aware Letter**

We refer to your letter dated 20 July 2026 regarding when Lotus Resources Limited (**Company** or **LOT**) become aware of certain information.

The Company does not intend that the disclosure provided to ASX in this letter to lift its current suspension from trading in its securities. The Company intends for its present suspension to continue until such time as it finalises a strategic funding package critical to the ongoing financial viability of the Company and its subsidiaries.

Regarding answers to your questions below, we respond as follows:

- 1. Does LOT consider the following information, or any part thereof, to be information that a reasonable person would expect to have a material effect on the price or value of its securities**
  - 1.1 The extent of damage and rectification works to the Kayelekera acid plant which occurred during hot commissioning of the acid plant**

Yes.
  - 1.2 Delays to production at the Kayelekera Project resulting in LOT being incapable of meeting its initial offtake obligation to deliver 1.01Mlbs of U<sub>3</sub>O<sub>8</sub> in 2H CY2026.**

Yes.
  - 1.3 LOT's liability under its offtake agreements was approximately US\$10 million in the event no deliveries could be made and no customers would agree to defer any deliveries in 2H CY2026.**

No.
  - 1.4 LOT's need for external funding to ensure its continued financial viability and the operations at the Kayelekera Project.**

Yes.
  - 1.5 The initiation of the Process Optimisation Program designed to transition from restart and commissioning activities to steady state production.**

No.



- 1.6 The recommendations under the Novamet metallurgical accounting and reconciliation process review. Noting in particular that LOT has confirmed the review is being finalised to *“support the reassessment and potential restatement of certain processing and metallurgical information, including as to recoveries, previously retracted for the period to December 2025”*.

No.

- 1.7 LOT’s statement that 124k lbs of U<sub>3</sub>O<sub>8</sub> produced from the Kayelekera Project remains subject to final assay and classification to determine if it is on-specification, and 93k lbs of U<sub>3</sub>O<sub>8</sub> is off-specification. Noting in particular that LOT has stated *“[v]arious options for this product will be considered by the Company including blending to achieve acceptance specifications or price discounting in order to be sold”*.

No.

2. If the answer to any part of question 1 is “no”, please advise the basis for that view.

**1.3 US\$10M Maximum Liability Estimate under Offtake Agreements**

The Maximum Liability Estimate under Offtake Agreements is not material in and of itself. Listed entities do not disclose theoretical maximums of exposure under contracts that they continue to be able to be performed in accordance with the contract's terms. A disclosure obligation will only potentially arise where an entity becomes aware that such contract is no longer capable of being performed.

The Maximum Liability Estimate was provided to assist investors in understanding the maximum potential quantum of any potential liability and short-term funding requirement. The Company notes the update to the ASX on 16 July 2026 that the Company has deferred 0.11 Mlbs and forecasts it will be able to deliver 0.20Mlbs, leaving 0.70Mlbs under negotiation.

The Company has continually disclosed its current offtake for CY2026, including 2H CY2026 delivery obligations. See for example the December 2025 Quarterly Activities Report, which stated *“90% of 2026 contracted commitments (1,000,000 lbs) are for 2H CY deliveries”* and March Quarterly Activities Report, which stated *“100% of 2026 contracted commitments (1,000,000 lbs) are for H2 CY26 deliveries.”*

The Company has provided guidance on the pricing for its offtake arrangements. For example, refer to ASX Announcements dated 3 September 2024, 29 January 2025, 17 March 2025, and 7 April 2026. Relevant information is also disclosed in its “Commitments” in its 2025 Annual Financial Report (ASX Announcement dated 24 September 2025).

The pricing guidance provides sufficient information for investors to assess the materiality of the mark-to-market value of the Company’s committed offtake against the publicly available uranium spot market price.

**1.5 Initiation of the Process Optimisation Program**

The Process Optimisation Program is not material in cost and the broad matters have been continuously discussed, including as noted in the ASX Aware Letter dated 11 May 2026 in relation to the “capital upgrades” (refer to responses to Question 2 in connection with 1.14 and Question 5.3 in the ASX Aware Letter dated 11 May 2026).



### **1.6 Novamet Metallurgical Accounting and Reconciliation Process Review**

As noted in the response to Question 1.1 in the ASX Aware Letter dated 11 May 2026, the Company does not consider reassessment and potential restatement of certain processing and metallurgical information as material information.

The material production metric for the Company is "Uranium Produced". The Company has disclosed the Uranium Produced in the December 2025 Quarterly Activities Report, updated the Uranium Produced on 1 April 2026 for the period to 31 December 2025 following reconciliation with independent laboratory tests, disclosed the Uranium Produced in the March 2025 Quarterly Activities Report, disclosed Uranium Produced for April and May 2026 on 25 June 2026 and June Quarter total on 16 July 2026.

The Company notes that recovery, head grade and ore milled are all key inputs into calculating Uranium Produced. The Company has not provided any guidance regarding these key inputs for the ramp-up period of Kayelekera, which are material assumptions in relation to its Accelerated Restart Plan and Ore Reserve which relate to steady state production only. These key inputs are only material if the material assumptions relevant to the key inputs no longer have foundation as they relate to steady state production. To date, the Company has no basis to believe there is any change in these material assumptions as they relate to steady state production at Kayelekera.

### **1.7 Off-specification Product and Product Pending Final Assay and Classification**

The existence of off-specification  $U_3O_8$  product is only material if the forecast loss of revenue from that off-specification is material to the Company.

The 93k lbs of off-specification  $U_3O_8$  product is not material in the context of:

- the off-specification product is still able to generate revenue, as indicated by the Company in its commentary in the ASX Announcement dated 16 July 2026, which includes blending or price discounting). The Company is still considering blending and price discount options; and
- the Company's current ramp-up of operations, where initial production typically experiences issues with product quality until steady state plant operations are achieved.

The Company disclosed on 1 April 2026 that acceptance of its product at Orano CE's conversion facility was subject to Lotus providing independent laboratory tests as condition for initial shipments to Orano CE. The fact that 124k lbs is subject to final assay and classification to determine if it is on-specification is not material. The Company notes that this 124k lbs relates solely to June 2026 Quarter production and that assaying of uranium concentrates takes a significant time for permitting export of product samples to South Africa, assaying at the laboratory and then review of the assaying results by Orano CE.

## **3. When did LOT first become aware of the information referred to in question 1 above**

### **1.1 Extent of Damage and Rectification to the Acid Plant**

The Company first became aware of the extent of the damage to the acid plant after market on 17 June 2026. The Company first became aware of the extent of rectification requirements to the acid plant on 20 June 2026 following inspection by a specialist, and the duration of the interim rectification time on 24 June 2026.



The materiality of the matter was also connected with the availability, reliability and cost of sulphuric acid.

Given the complexities involved, the Company utilised a request for suspension from quotation to adequately manage its continuous disclosure obligations until such time when it had conclusively understood the full impact of damage to the acid plant, rectification requirements (in particular time for the rectification works) and the consequent impact on operations.

### **1.2 Incapable of Meeting its Initial Offtake Obligations**

After market on 17 June 2026, when the Company became aware of the extent of damage to the acid plant.

Following becoming aware of this information, the Company proactively requested a trading halt pre-market open on 18 June 2026. In the following days, the Company prudently assessed key variables unknown at the time of entering trading halt relevant to its operational performance; availability, reliability and cost of sulphuric acid; production profile; offtake contracts; and financial decisions for the Company. Given the complexities involved, the Company utilised a request for suspension from quotation to adequately manage its continuous disclosure obligations until such time when it had conclusively understood the full impact of damage to the acid plant.

The decision the company made to temporarily suspend production on 25 June 2026, crystallised the disclosure made on 25 June 2026 that there would be "limited ability to deliver into these offtake obligations". Prior to that time, the Company had a reasonable basis to consider that these offtake obligations would be met.

### **1.3 US\$10M Maximum Liability Estimate under Offtake Agreements**

On 24 June 2026, when calculating the delivery obligations for 2H CY2026 and the difference in the contractual price and prevailing spot price.

Refer to Question 2 in connection with 1.3.

### **1.4 External Funding Requirement**

On 24 June 2026, following assessment of anticipated delays in production due to damage to the acid plant and acid supply issues, the consequential impacts of being unable to deliver impacted production and forecast expenditure requirements.

### **1.5 Initiation of the Process Optimisation Program**

On 18 March 2026. The process optimisation initiatives were formalised into a combined project and budget by the Kayelekera Processing Manager and approved on 18 March 2026.

### **1.6 Novamet Metallurgical Accounting and Reconciliation Process Review**

On 3 July 2026, the Company received an interim report from Novamet. The interim report was a review of metallurgical accounting processes and methodologies. It included a review of the various measurement points within the process flow sheet to confirm the veracity of data and understand the gaps in accounting for losses through the processing circuit.

A recommended improvement plan was included in the report as well as a draft methodology to allocate the historical production parameters. This methodology and



allocation of historical production parameters is going through final reviews between Novamet and site and therefore is not yet finalized.

**1.7 Off-specification Product and Product Pending Final Assay and Classification**

With respect to the full 93k lbs of off-specification product, after market on 19 June 2026 following receipt of classification from Orano CE of product which was either in specification or off-specification. A description of the immateriality of this information is set out in Question 2 in connection with 1.7.

In respect of the 124k lbs that remain subject to final assay and classification, after market on 15 July 2026, following completion of reconciliation of June 2026 production.

4. **If LOT first became aware of the information referred to in question 1 before the date of the March Quarterly Announcement, did LOT make any announcement prior to that date which disclosed the information? If not, please explain why the information was not released to the market at an earlier time, commenting specifically on when you believe LOT was obliged to release the information under Listing Rules 3.1 and 3.1A and what steps LOT took to ensure that the information was released promptly and without delay.**

**1.1 Extent of Damage and Rectification to the Acid Plant**

Not applicable.

**1.2 Incapable of Meeting its Initial Offtake Obligations**

Not applicable.

**1.3 US\$10M Maximum Liability Estimate under Offtake Agreements**

Refer to the response to Question 2 in connection with 1.3.

Prior to its March Quarterly Announcement, the Company made multiple disclosures providing sufficient information to allow investors to understand its maximum theoretical financial exposure at a given point in time.

**1.4 External Funding Requirement**

Not applicable.

**1.5 Initiation of the Process Optimisation Program**

Refer to the response to Question 2 in connection with 1.5, noting that the decision to initiate the Process Optimisation Program was not taken until 18 March 2026 and that undertaking this process in and of itself is not material.

On this basis, the Company does not consider that this individual information was required to be disclosed under Listing Rules 3.1 and 3.1A, though the Company provided it as additional context to the on-site activities being undertaken as detailed in the 16 July Announcement (titled "Kayelekera Project and Voluntary Suspension Update").

**1.6 Novamet Metallurgical Accounting and Reconciliation Process Review**

Not applicable

**1.7 Off-specification Product and Product Pending Final Assay and Classification**

Not applicable.



5. **When does LOT anticipate receiving the final assay and classification results for the 124k lbs of U<sub>3</sub>O<sub>8</sub> which is currently 'subject to final assay and classification'?**  
Approximately mid to late August 2026 for all 124 k lbs.
6. **Has Orano completed its Commissioning Material Review as contemplated in LOT's 1 April 2026 Announcement?**  
Yes.
7. **If the answer to question 6 is 'yes', what date did Orano complete the Commissioning Material Review and what date did LOT receive the results?**  
8 April 2026.
8. **If the answer to question 6 is 'no', when does LOT anticipate Orano's Commissioning Material Review will be completed?**  
Not applicable.
9. **Given the disclosure in LOT's July Update Announcement that of the 332k lbs of U<sub>3</sub>O<sub>8</sub> produced to date at the Kayelekera Project to date, 65% [o]f the ore produced is either subject to final assay and classification or off specification. Is any of this material capable of acceptance by Orano?**  
Yes.
10. **If the answer to question 9 is 'yes', please provide details.**  
The 124k lbs remain subject to assaying and classification and therefore remain potentially capable of acceptance by Orano.  
  
In relation to the 93k lbs of off-specification U<sub>3</sub>O<sub>8</sub> product, this material is potentially capable of acceptance by Orano outside its standard terms for acceptance of U<sub>3</sub>O<sub>8</sub> (i.e. at a discount, or increased treatment charges or penalties for impurities).  
  
The Company notes that part of the off-specification product relates to at least one impurity which remains under review, with the Company's independent laboratory consistently reporting higher levels of impurities than that tested by other assay laboratories (including Orano CE's). The Company is undertaking a duplicate testing at other assay laboratories to provide comparative results, and this may result in some off-specification product being classified as within specification.
11. **If the answer to question 9 is 'no', please provide details.**  
Not applicable.
12. **Having regard to LOT's recent disclosures, including in relation to classification of material produced to date at the Kayelekera Project, has Orano imposed any new conditions or varied existing conditions on it accepting ore from the Kayelekera Project?**  
No.
13. **If the answer to question 12 is 'yes', please provide details.**  
Not applicable.



- 14. Is LOT continuing to engage with ConverDyn and Cameco on accreditation? If yes, please provide details including any timeframes by which LOT expects the Accreditation Process may complete, or any other information material to understanding progress made to date by LOT in achieving accreditation by either ConverDyn or Cameco.**

Lotus is not actively seeking accreditation at this point in time but discussions have not ceased.

The Company notes that accreditation (qualification) is not necessary for the Company to be able to deliver product to customers from these converters. As disclosed by the Company in its March Quarterly Activities Report dated 30 April 2026, the ability to exchange or swap product between converters means an Orano CE account provides delivery flexibility across all contracts, sales and deliveries. Given this, Lotus does not consider that the decision to cease active accreditation from these parties to be material information.

The last active discussion with ConverDyn was on 11 May 2026 and with Cameco was on 3 March 2026.

The Company notes that the decision to cease actively progressing qualification with Cameco and ConverDyn was primarily a result of the change in shipping route from Dar Es Salaam to Walvis Bay (refer to ASX announcement dated 10 March 2026). Walvis Bay has a direct and frequent shipping route from Walvis Bay to Europe (Orano CE is located in France). However, there is no regular direct shipping route to North America from Walvis Bay (ConverDyn is located in USA and Cameco in Canada). The regular shipping route to North America from Walvis Bay requires the product to be shipped to Singapore (effectively backwards), before being transhipped to a vessel departing to North America from Singapore. This route significantly increasing shipping transit time and subsequently increases working capital requirements of the Company (as the time to revenue realisation of its product is significantly longer).

- 15. If the answer to question 14 is 'no', please provide the date LOT ceased the Accreditation Process engagement with ConverDyn and/or Cameco.**

Not applicable.

- 16. In the Response to ASX Aware Query, LOT confirmed "steady state production is expected to be achieved within Q3 CY2026", while each of the June Update Announcement and July Update Announcement confirmed steady-state production was targeted for "late CY2026". To that end:**

- 16.1 Does LOT expect to achieve steady-state production within Q3 or Q4 CY2026?**

Q4 CY2026. This change is a result of the impact to production announced in the 25 June 2026 ASX Announcement.

- 16.2 When does LOT expect to complete all of the actions recommended under the Process Optimisation Program?**

By the end of September 2026.



17. In respect of the Process Optimisation Program, is there any cost LOT will incur to undertake the actions required or recommended under the Process Optimisation Program? If yes, please confirm the expected costs.

The budgeted cost is US\$3.1 million, of which approximately US\$1.4 million has been spent to 30 June 2026.

18. If the answer to question 17 is 'yes', does LOT consider the cost of the actions required or recommended under the Process Optimisation Program will have, or are likely to have, a material impact on LOT's financial condition?

No.

19. Noting that LOT is considering options for the sale of 124k lbs of U<sub>3</sub>O<sub>8</sub> subject to final assay and classification and 93k lbs of U<sub>3</sub>O<sub>8</sub> that is off-specification (including by blending to achieve specification requirements or discounting the sale price), does LOT consider the execution of those options to achieve the sale will have, or are likely to have, a material impact on LOT's financial condition?

No. Please refer the responses to Questions 2 (in connection with 1.7) and 10.

20. In the event LOT is unable to re-negotiate its offtake obligations for the remainder of CY2026, how does LOT intend to fund a potential liability of up to US\$7 million, being that last known estimate of liability in the July Update Announcement?

As stated in the July Update Announcement, the Company has deferred 0.11 MLbs and forecasts it will be able to deliver 0.20MLbs, leaving 0.70MLbs under negotiation.

The Company intends to fund the potential liability of up to US\$7 million via an equity raise and/or quasi equity options and this liability will be specifically referenced in any use of proceeds resulting from such capital raising.

21. LOT's response to question 8.1 of the ASX Aware Query stated (amongst other things) that *"Lotus has not determined revised recovery rates for the December 2025 quarter. Lotus will not be able to accurately reconcile precise numbers given that it is not possible to accurately and retrospectively separate and allocate the inputs into the variables used to calculate Uranium Produced, particularly during a ramp up period of intermittent operations"*. However, the Novamet metallurgical accounting and reconciliation process review appears to be targeting a restatement of recovery information for the previously retracted period to December 2025. To that end, could you please confirm:

- 21.1 When did LOT become aware it would be possible to determine revised recovery information for the December 2025 quarter?

The Novamet metallurgical accounting and reconciliation process cannot accurately reconcile precise numbers for the reasons stated above and the position stated in the Company's response to Question 8.1 in the ASX Aware Query has not changed.

As stated in the ASX Aware Letter in response to Question 8.1, the purpose of the Novamet process was to *"determine an auditable and appropriate basis for assumptions and allocations of the abovementioned variables for the December 2025 quarter... The Company will determine final recovery numbers on a going-forward basis in consultation with the metallurgical consultants and its auditor based on the best information available to it."*



**21.2** What information or circumstances have changed in order for LOT to now be capable of determining revised recovery information for the December 2025 quarter?

Not applicable.

**22.** Please confirm that LOT is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

Yes.

**23.** Please confirm that LOT's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of LOT with delegated authority from the board to respond to ASX on disclosure matters.

The Company confirms that the above response has been authorised by the Board.

Yours sincerely,

Hayden Bartrop  
**Company Secretary**

20 July 2026

Mr Hayden Bartrop  
Company Secretary  
Lotus Resources Limited

By email

Dear Mr Bartrop

**Lotus Resources Limited ('LOT'): ASX Aware Letter**

ASX refers to the following:

- A. LOT's announcement titled "Kayelekera Uranium Accepted by Orano Conversion Facility" marked as 'price sensitive' and released to the ASX Market Announcement Platform ('MAP') on 1 April 2026 which stated:

*"Lotus has been working closely with Orano over recent months as part of an iterative process to optimise and qualify its product. Orano CE has agreed to accept Kayelekera's product, with Lotus providing independent laboratory testing results as a condition for initial shipments to Orano CE."*

*Orano CE is also currently reviewing the acceptance of material produced during the commissioning phase in Q4 2025" ('Commissioning Material Review')*

- B. LOT's Quarterly Activities Report for the quarter ended 31 March 2026 released to MAP on 30 April 2026 which stated the following:

1.1 *"Lotus has been working closely with Orano Chimie-Enrichissement (Orano CE) over recent months as part of an iterative process to optimise and qualify its product. Orano CE has now agreed to accept Kayelekera's product, with Lotus providing independent laboratory testing results as a condition for initial shipments to Orano CE."* ('Orana Product Acceptance') (ASX emphasis added).

1.2 *"Whilst the Company will continue to work towards accreditation with the other two western converters, ConverDyn and Cameco, the ability to exchange or swap product between converters means an Orano CE account provides delivery flexibility across all contracts, sales and deliveries."* ('Accreditation Process')

- C. LOT's response to ASX Aware Letter released to MAP on 11 May 2026 disclosing (amongst other things) that (ASX's questions in **bold**):

- 1.1 In response to question 6.1 and 6.2:

**"6.1 Does LOT maintain the timeframe included in its announcement date 7 April 2026, namely that LOT expected to achieve steady-state production (ie. by achieving production rates of 200klb per month, or an equivalent of approximately 2.4Mlbpa) during Q2 CY2026?"**

No.

*... The Company continues to expect to trend towards steady state production, but it does not expect to achieve a full month production rate of 200klb per month in one of the months in Q2 CY2026.*

**6.2 If the answer to question 6.1 is 'no', please confirm the revised timeframe in which steady-state production is expected to be achieved.**

*Based on current forecasts, full month steady state production is expected to be achieved within Q3 CY2026 (1Q FY2027). This is subject to the timing of a potential planned maintenance shutdown during the September quarter and finalisation of the FY2027 budget which is currently being developed."*

1.2 In response to question 8.1:

***“8.1 Has LOT has determined revised recovery rates for the December 2025 quarter? If so, what is the revised recovery rate?”***

*Lotus has not determined revised recovery rates for the December 2025 quarter. Lotus will not be able to accurately reconcile precise numbers given that it is not possible to accurately and retrospectively separate and allocate the inputs into the variables used to calculate Uranium Produced, particularly during a ramp up period of intermittent operations. The Company can only make inferences from the historical information and additional testing of tailings information. Please refer to the comments in response to Question 5.2 regarding the complexity in calculating the recovery.”*

D. LOT’s request for voluntary suspension released to MAP on 22 June 2026 stating that LOT requested a voluntary suspension under Listing Rule 17.2 for the following reasons:

- “(i) the Company is not yet in a position to make an announcement regarding a project and operational update for the Kayelekera Project (Announcement), in particular an update as to delayed arrival of procured acid supply and the extent of damage and rectification works to the acid plant (which occurred during hot commissioning of the acid plant); and*
- (ii) the delay in acid deliveries and acid plant damage creates a series of other operational, production, offtake contracts, and financial decisions for Lotus Resources, of which key variables are not yet known (Consequential Impacts)”*

E. LOT’s announcement titled “Kayelekera Project and Funding Update, Suspension Extension” released to MAP on 25 June 2026 (‘June Update Announcement’) disclosing (amongst other things) that:

- 1.1 *“Following final stages of hot commissioning works at the Kayelekera acid plant and the first production of acid, several refractory bricks within the sulphur furnace showed signs of failure. Lotus, with support from specialist engineers, has investigated the root cause of the failure and formulated a repair plan using additional refractory bricks available onsite with this work now underway.”*

- 1.2 *“Delays to production and export permitting impact the Company’s ability to meet its initial offtake obligations. At present, Lotus has obligations to deliver 1.01Mlbs of U3O8 in 2H CY2026.*

*Given limited ability to deliver into those offtake obligations, Lotus continues to engage with its customers to defer delivery of a significant proportion of those deliveries into CY2027.*

*Under its offtake agreements, Lotus’ financial exposure in the event of a delivery shortfall is limited to the difference between the price paid by the utility to procure replacement material and the contracted sales price (together with any associated legal costs or procurement commissions). Based on a uranium spot price of US\$85/lb of U3O8, Lotus’ maximum liability for 2026 is approximately US\$10 million (assuming no deliveries were able to be made and no customers agreed to defer any deliveries for 2026).”*

- 1.3 *“Lotus presently maintains a cash balance of US\$26 million (A\$37 million) (as at 22 June 2026). External funding, via a combination of sources (including Mercuria), is necessary to ensure the continued financial viability of Lotus and the operations at the Kayelekera mine, which has been the subject of the challenging operating conditions discussed above...*

*The Company is actively progressing equity and quasi-equity funding options, which remain subject to the Company demonstrating commissioning of the acid plant, a demonstrable pathway to sustainable steady-state production and resolution of offtake commitments for 2026 (Funding Process).”*

- 1.4 *“Subject to acid supply and funding, steady-state production is now expected later in CY2026”.*

F. LOT's announcement titled "Kayelekera Project and Voluntary Suspension Update" released to MAP on 16 July 2026 ('July Update Announcement') disclosing (amongst other things) that:

1.1 *"As part of the plan to address operational constraints, Lotus initiated a processing optimisation program, which was designed to support the transition from restart and commissioning activities to sustainable steady-state production. Key initiatives are focussed on:*

- *processing plant reliability and availability improvements;*
- *maintenance planning and execution enhancements;*
- *instrumentation and process control upgrades;*
- *recovery improvement; and*
- *laboratory capability.*

*The temporary production pause provided an opportunity to accelerate optimisation and planned maintenance activities that were originally scheduled for later in Q3 CY2026, enabling these works to be completed while production was suspended and reducing the likelihood of future operational interruptions.*

*With these initiatives substantially advanced, and acid plant repairs completed, the Company believes Kayelekera is well positioned to resume operations and continue the ramp-up of production."*

(together, the 'Process Optimisation Program')

1.2 *"As described in the March 2026 Quarterly Activities Report dated 30 April 2026, Lotus commissioned a comprehensive metallurgical accounting and reconciliation process review to assess the reliability of the metallurgical balance for the period January 2026 to May 2026. The review, undertaken by engineering group Novamet (Pty) Limited (Novamet), considered the principal measurement, sampling, analytical and reconciliation points used to account for uranium across plant feed, intermediate streams, tailings and final product.*

*The review identified opportunities to improve the accuracy of plant feed measurement and sampling systems for both plant feed tonnes and plant feed grade. These recommendations reinforce improvement initiatives identified by Lotus in its current optimisation program...*

*Novamet is finalising its work to support the reassessment and potential restatement of certain processing and metallurgical information, including as to recoveries, previously retracted for the period to December 2025, as outlined in the Company's March 2026 Quarterly Activities Report dated 30 April 2026"*

1.3 *"Since recommencing production at Kayelekera, the Company has produced a total of 332k lbs of U3O8.*

*Of this production:*

- *115k lbs has been classified as on-specification material;*
- *124k lbs remains subject to final assay and classification; and*
- *93k lbs mainly relating to early production is off specification.*

*Various options for this product will be considered by the Company including blending to achieve acceptance specifications or price discounting in order to be sold."*

1.4 *"At the time of the suspension announcement, Lotus had contractual delivery commitments of approximately 1.01Mlbs of U3O8 for the second half of CY2026.*

*Through constructive engagement with customers, the Company has successfully restructured a portion of these obligations through delivery deferrals...*

*As a result of the restructuring completed to date, Lotus estimates its maximum financial settlement exposure relating to CY2026 delivery obligations has reduced to approximately US\$7 million (based on an assumed US\$85/lb spot price) and continued negotiations seek to reduce this exposure further."*

- 1.5 *"Steady-state production continues to be targeted for late CY2026 at an annualised run rate of approximately 2.4Mlbs U3O8".*
- G. Listing Rule 3.1, which requires a listed entity to immediately give ASX any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities.
- H. The definition of "aware" in Chapter 19 of the Listing Rules, which states that:
- "an entity becomes aware of information if, and as soon as, an officer of the entity (or, in the case of a trust, an officer of the responsible entity) has, or ought reasonably to have, come into possession of the information in the course of the performance of their duties as an officer of that entity."*
- I. Section 4.4 in *Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B* titled "When does an entity become aware of information?"
- J. Listing Rule 3.1A, which sets out exceptions from the requirement to make immediate disclosure as follows.
- "3.1A Listing rule 3.1 does not apply to particular information while each of the following is satisfied in relation to the information:*
- 3.1A.1 One or more of the following 5 situations applies:*
- It would be a breach of a law to disclose the information;*
  - The information concerns an incomplete proposal or negotiation;*
  - The information comprises matters of supposition or is insufficiently definite to warrant disclosure;*
  - The information is generated for the internal management purposes of the entity; or*
  - The information is a trade secret; and*
- 3.1A.2 The information is confidential and ASX has not formed the view that the information has ceased to be confidential; and*
- 3.1A.3 A reasonable person would not expect the information to be disclosed."*
- K. The concept of "confidentiality" detailed in section 5.8 of *Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B* ('Guidance Note 8'). In particular, Guidance Note 8 states that:
- "Whether information has the quality of being confidential is a question of fact, not one of the intention or desire of the entity. Accordingly, even though an entity may consider information to be confidential and its disclosure to be a breach of confidence, if it is in fact disclosed by those who know it, then it is no longer a secret and it ceases to be confidential information for the purposes of this rule."*

#### **Request for information**

Having regard to the above, ASX asks LOT to respond separately to each of the following questions:

1. Does LOT consider the following information, or any part thereof, to be information that a reasonable person would expect to have a material effect on the price or value of its securities?
- 1.1 The extent of damage and rectification works to the Kayelekera acid plant which occurred during hot commissioning of the acid plant.
  - 1.2 Delays to production at the Kayelekera Project resulting in LOT being incapable of meeting its initial offtake obligation to deliver 1.01Mlbs of U<sub>3</sub>O<sub>8</sub> in 2H CY2026.
  - 1.3 LOT's liability under its offtake agreements was approximately US\$10 million in the event no deliveries could be made and no customers would agree to defer any deliveries in 2H CY2026.
  - 1.4 LOT's need for external funding to ensure its continued financial viability and the operations at the Kayelekera Project.
  - 1.5 The initiation of the Process Optimisation Program designed to transition from restart and commissioning activities to steady state production.
  - 1.6 The recommendations under the Novamet metallurgical accounting and reconciliation process review. Noting in particular that LOT has confirmed the review is being finalised to *"support the reassessment and potential restatement of certain processing and metallurgical information, including as to recoveries, previously retracted for the period to December 2025"*.
  - 1.7 LOT's statement that 124k lbs of U<sub>3</sub>O<sub>8</sub> produced from the Kayelekera Project remains subject to final assay and classification to determine if it is on-specification, and 93k lbs of U<sub>3</sub>O<sub>8</sub> is off-specification. Noting in particular that LOT has stated *"[v]arious options for this product will be considered by the Company including blending to achieve acceptance specifications or price discounting in order to be sold"*.
- Please answer separately for each of the above.
2. If the answer to any part of question 1 is "no", please advise the basis for that view.
- Please answer separately for each of the items in question 1 above.
3. When did LOT first become aware of the information referred to in question 1 above?
- Please answer separately for each of the items in question 1 above.
4. If LOT first became aware of the information referred to in question 1 before the date of the June Update Announcement or the July Update Announcement, did LOT make any announcement prior to that date which disclosed the information? If not, please explain why the information was not released to the market at an earlier time, commenting specifically on when you believe LOT was obliged to release the information under Listing Rules 3.1 and 3.1A and what steps LOT took to ensure that the information was released promptly and without delay.
- Please answer separately for each of the items in question 1 above and provide details of the prior announcement if applicable.
5. When does LOT anticipate receiving the final assay and classification results for the 124k lbs of U<sub>3</sub>O<sub>8</sub> which is currently 'subject to final assay and classification'?
6. Has Orano completed its Commissioning Material Review as contemplated in LOT's 1 April 2026 Announcement?
7. If the answer to question 6 is 'yes', what date did Orano complete the Commissioning Material Review and what date did LOT receive the results?

8. If the answer to question 6 is 'no', when does LOT anticipate Orano's Commissioning Material Review will be completed?
9. Given the disclosure in LOT's July Update Announcement that of the 332k lbs of U<sub>3</sub>O<sub>8</sub> produced to date at the Kayelekera Project to date, 65% if the ore produced is either subject to final assay and classification or off specification. Is any of this material capable of acceptance by Orana?
10. If the answer to question 9 is 'yes', please provide details.
11. If the answer to question 9 is 'no', please provide details.
12. Having regard to LOT's recent disclosures, including in relation to classification of material produced to date at the Kayelekera Project, has Orana imposed any new conditions or varied existing conditions on it accepting ore from the Kayelekera Project?
13. If the answer to question 12 is 'yes', please provide details.
14. Is LOT continuing to engage with ConverDyn and Cameco on accreditation? If yes, please provide details including any timeframes by which LOT expects the Accreditation Process may complete, or any other information material to understanding progress made to date by LOT in achieving accreditation by either ConverDyn or Cameco.
15. If the answer to question 14 is 'no', please provide the date LOT ceased the Accreditation Process engagement with ConverDyn and/or Cameco.
16. In the Response to ASX Aware Query, LOT confirmed "*steady state production is expected to be achieved within Q3 CY2026*", while each of the June Update Announcement and July Update Announcement confirmed steady-state production was targeted for "*late CY2026*". To that end:
- 16.1 Does LOT expect to achieve steady-state production within Q3 or Q4 CY2026?
- 16.2 When does LOT expect to complete all of the actions recommended under the Process Optimisation Program?
17. In respect of the Process Optimisation Program, is there any cost LOT will incur to undertake the actions required or recommended under the Process Optimisation Program? If yes, please confirm the expected costs.
18. If the answer to question 17 is 'yes', does LOT consider the cost of the actions required or recommended under the Process Optimisation Program will have, or are likely to have, a material impact on LOT's financial condition?
19. Noting that LOT is considering options for the sale of 124k lbs of U<sub>3</sub>O<sub>8</sub> subject to final assay and classification and 93k lbs of U<sub>3</sub>O<sub>8</sub> that is off-specification (including by blending to achieve specification requirements or discounting the sale price), does LOT consider the execution of those options to achieve the sale will have, or are likely to have, a material impact on LOT's financial condition?
20. In the event LOT is unable to re-negotiate its offtake obligations for the remainder of CY2026, how does LOT intend to fund a potential liability of up to US\$7 million, being that last known estimate of liability in the July Update Announcement?
21. LOT's response to question 8.1 of the ASX Aware Query stated (amongst other things) that "*Lotus has not determined revised recovery rates for the December 2025 quarter. Lotus will not be able to accurately reconcile precise numbers given that it is not possible to accurately and retrospectively separate and allocate the inputs into the variables used to calculate Uranium Produced, particularly during a ramp up period of intermittent operations*". However, the Novamet metallurgical accounting and reconciliation process review

appears to be targeting a restatement of recovery information for the previously retracted period to December 2025. To that end, could you please confirm:

21.1 When did LOT become aware it would be possible to determine revised recovery information for the December 2025 quarter?

21.2 What information or circumstances have changed in order for LOT to now be capable of determining revised recovery information for the December 2025 quarter?

Please answer separately in relation to each question above.

22. Please confirm that LOT is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

23. Please confirm that LOT's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of LOT with delegated authority from the board to respond to ASX on disclosure matters.

#### **When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **2:00 PM AWST Thursday, 23 July 2026**.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, LOT's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out above and may require LOT to request a trading halt immediately if trading in LOT's securities is not already halted or suspended.

Your response should be sent by e-mail to **ListingsCompliancePerth@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow us to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

#### **Suspension**

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in LOT's securities under Listing Rule 17.3.

#### **Listing Rules 3.1 and 3.1A**

In responding to this letter, you should have regard to LOT's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*. It should be noted that LOT's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

#### **Release of correspondence between ASX and entity**

We reserve the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under listing rule 18.7A. The usual course is for the correspondence to be released to the market.

Yours faithfully

---

ASX Supervision